That said, we believe that the observed genetic enrichment of ultra-rare variants before APOE status and sex correction in our relatively small cohort size endorses genetic screening in extended cohorts or integration of publicly available AD and FTD genetic data to substantially increase the power to test for a possible association with disease risk. This evidence concerns the gene APOE and Alzheimer disease.